Register
Login:
Share:
Email Facebook Twitter

Market analyst Rajan Dhall talks about the financial market Watch here

Market analyst Rajan Dhall talks about the financial market


Summit Ther Share Price (SUMM)



Share Price Information for Summit Ther (SUMM)


Share Price: 180.00Bid: 175.00Ask: 185.00Change: 0.00 (0.00%)No Movement on Summit Ther
Spread: 10.00Spread as %: 5.71%Open: 177.50High: 180.00Low: 177.50Yesterday’s Close: 180.00

Summit Therapeutics Plc Ord 1P

Summit Ther is listed in the FTSE AIM All-Share
Summit Ther is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
180.00

Share Price SpacerBid
175.00

Share Price SpacerAsk
185.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
12,600

Share Price SpacerOpen
177.50

Share Price SpacerHigh
180.00

Share Price SpacerLow
177.50

Share Price SpacerClose
180.00

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 61.91m £111.43m 1,500

52 Week High 260.00 52 Week High Date 4-OCT-2016
52 Week Low 90.00 52 Week Low Date 16-SEP-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
3 100 2,500 -5.143 -35.00 0.00 0.00


London South East Users info for Summit Ther




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

26-Jun-17
17:08:18
180.00
2,500
 
175.00
185.00
4,500
Trade Type:
Ordinary

26-Jun-17
15:21:07
178.11
100
Sell* 
175.00
185.00
178.11
Trade Type:
Ordinary

26-Jun-17
10:06:48
184.50
2,500
Buy* 
175.00
185.00
4,613
Trade Type:
Ordinary




View more Summit Ther trades >>

Directors Deals for Summit Ther (SUMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
David Wurzer held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 David Wurzer
2.33USD7,5007500
17-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Valerie Andrews held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 Valerie Andrews
2.3USD10,50010500
16-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Frank Armstrong held the position of Non-Executive Chairman at Summit Therapeutics at the time of this trade.
 Frank Armstrong
2.34USD4,25014442
View more Summit Ther directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Mon 12:56Free-MoneyRE: Glyn Edwards re DMD on RARECast180.00No Opinion
Thanks Chris, there's quite a degree of confidence in there that they'll be able to show efficacy.
Increasing the absorption with diet and reformulation seems to have done the trick.
I notice too that Glyn said of the year, so hopefully they'll have the results ready for publication nearer January than March. The risk reward is getting better all the time now. GLA.
Fri 20:02ChrisatrdgGlyn Edwards re DMD on RARECast177.50Strong Buy
RARECast - Glyn Edwards see Summit twitter a/c
Summit Pursues A Different Approach to Treating Duchenne
https://soundcloud.com/rarecast/summit-pursues-a-different-approach-to-treating-duchenne
Thu 21:58gmccRidinilazole: c-diff175.00No Opinion
If you had not seen these links : Mark Wilcox quite a good listen

"Ridinilazole: Preserving the Microbiome to Reduce CDI"

http://www.summitplc.com/video-archive/ridinilazole-preserving-microbiome-reduce-cdi/

http://www.summitplc.com/media/webcasts-videos/

Good luck everyone
Thu 16:35Free-MoneyRE: JMP Life Sciences Conf. 21 June 17175.00No Opinion
That's the minimum were hoping to see in Q1.

"The disease has an estimated incidence of 1 in 5,000 and a patient population in the developed world of around 50,000. Patients typically don’t live beyond their late 20s."

Hopefully if the treatment works it will at least double their lifespan, fingers and everything crossed.

Interestingly, if it works as hoped, that means peak drug sales would be much further down the road and higher than the usual 2-4 years after launch.… Read More
Thu 14:02gmccRE: JMP Life Sciences Conf. 21 June 17175.00No Opinion
Thanks Chris for sharing - a few new slides ! DMD comments sound quite positive !

"Company Presentation 20 June 2017"

“Potentially Positive Signals in PhaseOut DMD

Mechanism

Utrophin ----- More uniform distribution

Fiber regeneration - Decrease

Muscle Health : MRI --- Slowing or stabilization of fat fraction increase "

Good luck everyone !
Thu 13:05Free-MoneyRE: JMP Life Sciences Conf. 21 June 17175.00No Opinion
Thanks Chris, some graphic slides there on the effects of a C.Diff infection.
Good information and confidence of everything progressing to plan.
Just waiting for Ridi business cogs to turn and get P3 going.
Also the long wait for Q1 PhaseOut interim results.

All in all a fantastic investment at this price considering the relative short time scale to potential value inflection points and the scale of the value that could be recognised on good results..... see Sarepta June-Oct 2012 when… Read More

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Summit Ther (SUMM) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.